Canada - English - Health Canada

merck canada inc - indinavir (indinavir sulfate) - capsule - 200mg - indinavir (indinavir sulfate) 200mg - hiv protease inhibitors

Canada - English - Health Canada

merck canada inc - indinavir (indinavir sulfate) - capsule - 300mg - indinavir (indinavir sulfate) 300mg - hiv protease inhibitors

Canada - English - Health Canada

merck canada inc - indinavir (indinavir sulfate) - capsule - 400mg - indinavir (indinavir sulfate) 400mg - hiv protease inhibitors

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - quinine sulfate - oral tablet - 300mg

European Union - English - EMA (European Medicines Agency)

merck sharp & dohme b.v. - indinavir sulfate ethanolate - hiv infections - antivirals for systemic use - crixivan is indicated in combination with antiretroviral nucleoside analogues for the treatment of hiv-1 infected adults.,

United States - English - NLM (National Library of Medicine)

rebel distributors corp - indinavir sulfate (unii: 771h53976q) (indinavir - unii:5w6ya9pkkh) - indinavir 400 mg - crixivan in combination with antiretroviral agents is indicated for the treatment of hiv infection. this indication is based on two clinical trials of approximately 1 year duration that demonstrated: 1) a reduction in the risk of aids-defining illnesses or death; 2) a prolonged suppression of hiv rna. in all clinical studies, with the exception of actg 320, the amplicor hiv monitor assay was used to determine the level of circulating hiv rna in serum. this is an experimental use of the assay. hiv rna results should not be directly compared to results from other trials using different hiv rna assays or using other sample sources. study actg 320 was a multicenter, randomized, double-blind clinical endpoint trial to compare the effect of crixivan in combination with zidovudine and lamivudine with that of zidovudine plus lamivudine on the progression to an aids-defining illness (adi) or death. patients were protease inhibitor and lamivudine naive and zidovudine experienced, with cd4 cell counts of ≤200 cells/mm3

United States - English - NLM (National Library of Medicine)

state of florida doh central pharmacy - indinavir sulfate (unii: 771h53976q) (indinavir - unii:5w6ya9pkkh) - indinavir 400 mg - crixivan in combination with antiretroviral agents is indicated for the treatment of hiv infection. this indication is based on two clinical trials of approximately 1 year duration that demonstrated: 1) a reduction in the risk of aids-defining illnesses or death; 2) a prolonged suppression of hiv rna. in all clinical studies, with the exception of actg 320, the amplicor hiv monitor assay was used to determine the level of circulating hiv rna in serum. this is an experimental use of the assay. hiv rna results should not be directly compared to results from other trials using different hiv rna assays or using other sample sources. study actg 320 was a multicenter, randomized, double-blind clinical endpoint trial to compare the effect of crixivan in combination with zidovudine and lamivudine with that of zidovudine plus lamivudine on the progression to an aids-defining illness (adi) or death. patients were protease inhibitor and lamivudine naive and zidovudine experienced, with cd4 cell counts of ≤200 cells/mm3

United States - English - NLM (National Library of Medicine)

stat rx usa llc - indinavir sulfate (unii: 771h53976q) (indinavir anhydrous - unii:9mg78x43zt) - indinavir anhydrous 400 mg - crixivan in combination with antiretroviral agents is indicated for the treatment of hiv infection. this indication is based on two clinical trials of approximately 1 year duration that demonstrated: 1) a reduction in the risk of aids-defining illnesses or death; 2) a prolonged suppression of hiv rna. in all clinical studies, with the exception of actg 320, the amplicor hiv monitor assay was used to determine the level of circulating hiv rna in serum. this is an experimental use of the assay. hiv rna results should not be directly compared to results from other trials using different hiv rna assays or using other sample sources. study actg 320 was a multicenter, randomized, double-blind clinical endpoint trial to compare the effect of crixivan in combination with zidovudine and lamivudine with that of zidovudine plus lamivudine on the progression to an aids-defining illness (adi) or death. patients were protease inhibitor and lamivudine naive and zidovudine experienced, with cd4 cell counts of ≤200 cells/mm3

United States - English - NLM (National Library of Medicine)

merck sharp & dohme corp. - indinavir sulfate (unii: 771h53976q) (indinavir anhydrous - unii:9mg78x43zt) - indinavir anhydrous 100 mg - crixivan in combination with antiretroviral agents is indicated for the treatment of hiv infection. this indication is based on two clinical trials of approximately 1 year duration that demonstrated: 1) a reduction in the risk of aids-defining illnesses or death; 2) a prolonged suppression of hiv rna. in all clinical studies, with the exception of actg 320, the amplicor hiv monitor assay was used to determine the level of circulating hiv rna in serum. this is an experimental use of the assay. hiv rna results should not be directly compared to results from other trials using different hiv rna assays or using other sample sources. study actg 320 was a multicenter, randomized, double-blind clinical endpoint trial to compare the effect of crixivan in combination with zidovudine and lamivudine with that of zidovudine plus lamivudine on the progression to an aids-defining illness (adi) or death. patients were protease inhibitor and lamivudine naive and zidovudine experienced, with cd4 cell counts of ≤200 cells/mm3

United States - English - NLM (National Library of Medicine)

avera mckennan hospital - indinavir sulfate (unii: 771h53976q) (indinavir anhydrous - unii:9mg78x43zt) - indinavir anhydrous 400 mg